eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Abbott Healthcare Products Limited

Mansbridge Road, West End, Southampton, SO18 3JD
Telephone: +44 (0)2380 467 000
Fax: +44 (0)2380 465 350
Medical Information Direct Line: +44 (0)2380 467 000
Medical Information e-mail: medinfo.shl@abbott.com
Medical Information Fax: +44 (0)2380 474518

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Patient Information Leaflet last updated on the eMC: 27/02/2012
PIL Teveten 300mg, 400mg & 600mg film-coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 27/02/2012 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to drug interactions
  • Change to dosage and administration
Updated on 19/05/2011 and displayed until 27/02/2012
Reasons for adding or updating:
  • Change to appearance of the medicine
Updated on 15/02/2011 and displayed until 19/05/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change from BAN to rINN
  • Change to manufacturer contact details
  • Change to MA holder contact details
Updated on 02/11/2009 and displayed until 15/02/2011
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 15/05/2008 and displayed until 02/11/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
  • Joint PIL superseded by PILs for individual presentations
Updated on 14/06/2006 and displayed until 15/05/2008
Reasons for adding or updating:
  • Change to drug interactions
Updated on 27/02/2002 and displayed until 14/06/2006
Reasons for adding or updating:
  • Update to PIL
Updated on 30/07/2001 and displayed until 27/02/2002
Reasons for adding or updating:
  • Update to PIL
Updated on 11/05/2000 and displayed until 30/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   eprosartan mesilate